Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Glecirasib by Jacobio Pharmaceuticals Group for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Glecirasib is under clinical development by Jacobio Pharmaceuticals Group and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to...
Glecirasib by Jacobio Pharmaceuticals Group for Biliary Tumor: Likelihood of Approval
Glecirasib is under clinical development by Jacobio Pharmaceuticals Group and currently in Phase II for Biliary Tumor. According to GlobalData,...
Glecirasib by Jacobio Pharmaceuticals Group for Metastatic Pancreatic Cancer: Likelihood of Approval
Glecirasib is under clinical development by Jacobio Pharmaceuticals Group and currently in Phase II for Metastatic Pancreatic Cancer. According to...
Glecirasib by Jacobio Pharmaceuticals Group for Gastric Cancer: Likelihood of Approval
Glecirasib is under clinical development by Jacobio Pharmaceuticals Group and currently in Phase II for Gastric Cancer. According to GlobalData,...
JAB-30355 by Jacobio Pharmaceuticals Group for Solid Tumor: Likelihood of Approval
JAB-30355 is under clinical development by Jacobio Pharmaceuticals Group and currently in Phase II for Solid Tumor. According to GlobalData,...
JAB-30355 by Jacobio Pharmaceuticals Group for Small-Cell Lung Cancer: Likelihood of Approval
JAB-30355 is under clinical development by Jacobio Pharmaceuticals Group and currently in Phase II for Small-Cell Lung Cancer. According to...
JAB-30355 by Jacobio Pharmaceuticals Group for Gastric Cancer: Likelihood of Approval
JAB-30355 is under clinical development by Jacobio Pharmaceuticals Group and currently in Phase II for Gastric Cancer. According to GlobalData,...
JAB-30355 by Jacobio Pharmaceuticals Group for Pancreatic Cancer: Likelihood of Approval
JAB-30355 is under clinical development by Jacobio Pharmaceuticals Group and currently in Phase II for Pancreatic Cancer. According to GlobalData,...
JAB-30355 by Jacobio Pharmaceuticals Group for Ovarian Cancer: Likelihood of Approval
JAB-30355 is under clinical development by Jacobio Pharmaceuticals Group and currently in Phase II for Ovarian Cancer. According to GlobalData,...
JAB-30355 by Jacobio Pharmaceuticals Group for Breast Cancer: Likelihood of Approval
JAB-30355 is under clinical development by Jacobio Pharmaceuticals Group and currently in Phase II for Breast Cancer. According to GlobalData,...